Sign in
CompletedPhase 4

Surgery and durvalumab after chemoradiotherapy for hard-to-operate lung cancer

Tests surgery then durvalumab after chemoradiotherapy in adults with non-small cell lung cancer.

Key facts

Who runs it
Amsterdam UMC Stichting
Where
Amsterdam, NetherlandsSee the site
Registry title
ChemoRadiotherapy with Or Without surgery followed by consolidation Durvalumab (CROWD): a phase IV feasibility trial
Status
Completed
Phase
Phase 4
People taking part
38 people enrolled
Started
16 Dec 2024
Ended
13 Nov 2026
Type of study
Interventional
Record updated
12 December 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with stage III non-small cell lung cancer (not N3) who are first planned for chemoradiotherapy followed by durvalumab. It tests whether surgery after chemoradiotherapy is safe.

Age
18 years or older
Sex
All sexes can join
Disease stage
Stage III non-small cell lung cancer without N3 disease, confirmed by tissue or cell tests before chemoradiotherapy starts
Earlier treatment
The team first advised chemoradiotherapy followed by durvalumab, without surgery. People must not have had chemoradiotherapy schemes other than platinum doublet with 30 once-daily fractions of 2 Gy.
Biomarker or test result
If N2 disease is suspected, invasive staging of the mediastinum must prove it before chemoradiotherapy starts. People with known gene changes that can be treated cannot join.

Main reasons for not taking part

  • TxN3 or M1 disease
  • Chemoradiotherapy schemes other than platinum doublet with 30 once-daily fractions of 2 Gy
  • Cannot have surgery because of heart and lung function tests or other illnesses
  • Known gene changes that can be treated with targeted drugs

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Histologically or cytologically confirmed stage III (non-N3) NSCLC (TNM 8th edition), before start of chemoradiotherapy
  • In case of suspected N2-disease, mediastinal invasive staging (EUS, EBUS and/or mediastinoscopy) to prove N2 involvement before start of concurrent CRT is mandatory
  • Initial MDT recommendation for a non-surgical treatment comprising CRT followed by durvalumab

Who cannot take part

  • Patients with TxN3 or M1 disease
  • The use of any CRT schemes other than those in ESMO recommendations (platinum doublet, 30 once-daily fractions of 2 Gy)
  • Patients deemed inoperable based on cardiopulmonary function tests or comorbidity
  • Patients with known actionable genomic alterations

Where in Netherlands

  • Amsterdam UMC StichtingAmsterdam, NetherlandsNo longer taking part

About the trial

What the trial wants to find out

-to assess the safety of surgery in patients with initially unresectable stage III NSCLC who are considered resectable by the multidisciplinary team within 12 weeks after finishing high-dose CRT -to assess the ability to proceed to durvalumab consolidation therapy after surgery

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
ChemoRadiotherapy with Or Without surgery followed by consolidation Durvalumab (CROWD): a phase IV feasibility trial
Plain-language title
Surgery and durvalumab after chemoradiotherapy for hard-to-operate lung cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
12 December 2024